Skip to main content
. Author manuscript; available in PMC: 2009 Dec 22.
Published in final edited form as: J Pharmacol Exp Ther. 2007 Nov 21;324(2):484–496. doi: 10.1124/jpet.107.129890

Fig. 3.

Fig. 3

The deoxy analogs and MSVIII-19 differ in potency for pre-desensitization of GluR5-2a receptors. A, representative traces of glutamate-evoked currents (10 mM) before application of 1 μM 8-deoxy-neoDH (left) or 1 μM 9-deoxy-neoDH; subsequent glutamate-evoked currents in the presence of the analogs were attenuated by desensitization (right). B, inhibition-response curves for 8-deoxy-neoDH, 9-deoxy-neoDH, and MSVIII-19 (from Sanders et al., 2005) on recombinant GluR5-2a receptors. Logistic fits were constrained at the minima (0%) and maxima (100%), and IC50 values were determined to be 238 pM for 8-deoxy-neoDH and 151 and 23 nM for 9-deoxy-neoDH and MSVIII-19, respectively (Sanders et al., 2005), respectively. n = 3 to 5 for each concentration.